Prism Pharmaceuticals

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 9 drugs with upcoming expirations

Activity

Key Events

Jul 16, 2024FDAInlyta — INLYTA

Sep 26, 2023FDABosulif — BOSULIF

Sep 7, 2023FDAXalkori — XALKORI

Aug 18, 2023FDAPristiq — PRISTIQ

Sep 22, 2022FDAInlyta — INLYTA

Mar 22, 2022FDARapamune — HYFTOR

Nov 22, 2021FDARapamune — FYARRO

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Regulatory

Regulatory Timeline

20171 event

FDADec 19

Pristiq — PRISTIQ

Application NDA021992

20184 events

FDAAug 10

Inlyta — INLYTA

Application NDA202324

FDAAug 2

Tygacil — TIGECYCLINE

Application NDA211158 (NDA)

FDAFeb 6

Pristiq — PRISTIQ

Application NDA021992

FDAJan 18

Tygacil — TIGECYCLINE

Application NDA208744 (NDA)

20203 events

FDASep 25

Xeljanz — XELJANZ

Application NDA213082 (NDA)

FDAJun 4

Inlyta — INLYTA

Application NDA202324

FDAJan 23

Inlyta — INLYTA

Application NDA202324

20215 events

FDANov 22

Rapamune — FYARRO

Application NDA213312 (NDA)

FDANov 10

Pristiq — PRISTIQ

Application NDA021992

FDAOct 15

Chantix — TYRVAYA

Application NDA213978 (NDA)

FDAOct 15

Tyrvaya — TYRVAYA

Application NDA213978 (NDA)

FDASep 20

Pristiq — PRISTIQ

Application NDA021992

20222 events

FDASep 22

Inlyta — INLYTA

Application NDA202324

FDAMar 22

Rapamune — HYFTOR

Application NDA213478 (NDA)

20234 events

FDASep 26

Bosulif — BOSULIF

Application NDA217729 (NDA)

FDASep 26

Bosulif — BOSULIF

Application NDA217729 (NDA)

FDASep 7

Xalkori — XALKORI

Application NDA217581 (NDA)

FDAAug 18

Pristiq — PRISTIQ

Application NDA021992

20241 event

FDAJul 16

Inlyta — INLYTA

Application NDA202324

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)